Novel ferrocenylbisphosphonate hybrid compounds: Synthesis, characterization and potent activity against cancer cell lines

Simple item page
dc.contributor.authorAnusionwu, Chioma G.
dc.contributor.authorAderibigbe, Blessing A. 0000-0003-1157-7481
dc.contributor.authorAdeyemi, Samson A.
dc.contributor.authorUbanako, Philemon
dc.contributor.authorOselusi, Samson O.
dc.contributor.authorChoonara, Yahya E.
dc.contributor.authorMbianda, Xavier Yangkou
dc.date.accessioned2026-02-11T05:19:28Z
dc.date.available2026-02-11T05:19:28Z
dc.date.issued2022-02-02
dc.description.abstractThe toxicity of existing anticancer agents on healthy cells and the emergence of multidrug-resistance cancer cells have led to the search for less toxic anticancer agents with different mechanisms of action. In this study, a novel class of ferrocenylbisphosphonate hybrid compounds (H1-H8) were designed and characterized using NMR, IR and HRMS. The in vitro anticancer activity of the hybrid compounds on HeLa (cervix adenocarcinoma) and A549 (non-small cell lung cancer cell lines) was evaluated. The structure–activity relationship of the hybrid molecules was also studied. The lead compound, tetraethyl (3-(4-oxo-4-ferrocenylbutanamido) propane-1-1-diylbis (phosphonate) (H6) exhibited higher cytotoxicity on A549 (IC50 = 28.15 µM) than cisplatin (IC50 = 58.28 µM), while its activity on HeLa cells (IC50 = 14.69 µM) was equivalent to that of cisplatin 15.10 µM (HeLa cells). H6 (IC50 = 95.58 µM) was also five times less toxic than cisplatin (IC50 = 20.86 µM) on fibroblast NIH3T3 suggesting that H6 can be a future replacement for cisplatin due to its non-toxicity to healthy cells. Interestingly, some ferrocene and bisphosphonate parent compounds exhibited promising anticancer activity with 4-ferrocenyl-4-oxobutanoic acid (FI) exhibiting higher cytotoxic activity (IC50 = 1.73 µM) than paclitaxel (IC50 = 3.5 µM) on A549 cell lines. F1 also exhibited lower cytotoxicity than paclitaxel and cisplatin on the normal murine fibroblast cell line (NIH3T3). The molecular docking studies showed H6 strong binding affinity for the STAT3 signaling pathway in A549 cell line, and the MAdCAM-1 and cellular tumor antigen p53 proteins in HeLa cell lines.
dc.description.sponsorshipWe acknowledge the financial assistance of the National ResearchC.G. Anusionwu et al. Bioorganic & Medicinal Chemistry 58 (2022) 116652 11 Foundation and Medical Research Council (Self-Initiated Research) South Africa. Samson.O. Oselusi thanks the Centre for HighPerformance Computing (South Africa) for providing access to the computational resources used in this work.
dc.identifier.citationAderibigbe B; Anusionwu C; Adeyemi S; Ubanako P; Oselusi S; Choonara Y; Mbianda X (2022): Novel ferrocenylbisphosphonate hybrid compounds: synthesis, characterization and potent activity against cancer cell lines: Bioorganic and Medicinal Chemistry, 58. https://doi.org/10.1016/j.bmc.2022.116652
dc.identifier.issn1464-3391
dc.identifier.urihttp://hdl.handle.net/20.500.11837/3683
dc.language.isoen
dc.subjectFerrocenylbisphosphonate hybrids
dc.subjectAnticancer activity
dc.subjectCytotoxicity
dc.subjectMolecular docking
dc.titleNovel ferrocenylbisphosphonate hybrid compounds: Synthesis, characterization and potent activity against cancer cell lines
dc.typeArticle

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
1-s2.0-S096808962200044X-main.pdf
Size:
2.29 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Research Outputs